Pfizer And BioNTech Hope To Develop First mRNA Shingles Vaccine

Pfizer and BioNTech plan to develop the first mRNA vaccine against shingles, which is their third collaboration following the development of the first and most widely used mRNA coronavirus vaccine. “Adults aged 50 years and older as well as vulnerable populations like cancer patients are at an increased risk of shingles. Our goal is to develop an mRNA vaccine with a favorable safety profile and high efficacy, which is at the same time more easily scalable to support global access,”...
Article Type: 
Site Name:
FDA Issue: 
FDA Week - 01/07/2022
FDA Volume: 
Vol. 28, No. 1


Log in to access this content.

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.